The University of Tennessee Research Foundation (UTRF) has entered into a licensing agreement with CytoSen Therapeutics, Inc. for commercial rights to use the K-562 cell lines to produce an innovative natural killer (NK) cell therapy that harnesses the power of a person’s own immune cells to help fight cancer. Unlike other cell therapies, this approach has the potential to be used as a treatment component for many types of cancer.
UTRF News
WVLT article: ORNL, UTHSC Develop Program that Could Prevent Blindness from Diabetes
WVLT article: Find out about the new program could help prevent blindness from diabetes!
Funding Your Startups with SBIR Grants
Did you know the Federal Government supports technology commercialization?